Comparison of low dose versus ultra-low dose hormone therapy in menopausal symptoms and quality of life in perimenopause women

References

• Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96(3):351–358.
   PubMed Web of Science ®Google Scholar
• Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the women's health initiative. Obstet Gynecol. 2005;105(5 Pt 1):1063–1073.
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative Randomized Trials. JAMA. 2013;310(13):1353–1368.
   PubMed Web of Science ®Google Scholar
• Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2017;13(4):220–231.
   PubMed Web of Science ®Google Scholar
• Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas. 2007;57(1):81–84.
   PubMed Web of Science ®Google Scholar
• Peeyananjarassri K, Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric. 2005;8(1):13–23.
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A, et al. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150.
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Durand G, Kahler E, et al. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas. 2010;67(3):227–232.
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Levancini M. Hormone replacement therapy and the prevention of postmenopausal osteoporosis. Menopause Rev. 2014;13:213–220.
   Google Scholar
• Endrikat J, Graeser T, Mellinger U, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1 mg estradiol valerate/2 mg dienogest on hot flushes in postmenopausal women. Maturitas. 2007;58(2):201–207.
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Schaefers M, Uddin A, et al. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women. Menopause J N Am Menopause Soc. 2009;16(5):877–882.
   PubMed Web of Science ®Google Scholar
• Malik S, Pannu D, Prateek S, et al. Comparison of the symptomatic response in Indian menopausal women with different estrogen preparations for the treatment of menopausal symptoms: a randomized controlled trial. Arch Gynecol Obstet. 2016;293(6):1325–1333.
   PubMed Web of Science ®Google Scholar
• Files JA, Miller VM, Cha SS, et al. Effects of different hormone therapies on breast pain in recently postmenopausal women: findings from the Mayo Clinic KEEPS Breast Pain Ancillary Study. J Womens Health. 2014;23(10):801–805.
   PubMed Web of Science ®Google Scholar
• Worsley R, Bell RJ, Gartoulla P, et al. Low use of effective and safe therapies for moderate to severe menopausal symptoms: a cross-sectional community study of Australian women. Menopause. 2016;23(1):11–17.
   PubMed Web of Science ®Google Scholar
• Chu K, Song Y, Chatooah ND, et al. The use and discontinuation of hormone replacement therapy in women in South China. Climacteric. 2018;21(1):47–52.
   PubMed Web of Science ®Google Scholar
• Harlow SD, Gass M, Hall JE, et al. Executive summary of the stages of reproductive aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159–1168.
   PubMed Web of Science ®Google Scholar
• Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection. Med Care. 1992;30(6):473–483.
   PubMed Web of Science ®Google Scholar
• Rose MS, Koshman ML, Spreng S, et al. Statistical issues encountered in the comparison of health-related quality of life in diseased patients to published general population norms: problems and solutions. J Clin Epidemiol. 1999;52(5):405–412.
   PubMed Web of Science ®Google Scholar
• Almeida JPM, Carnide C, Branquinho M, et al. Impact of hormone replacement therapy on body weight. Rev Bras Ginecol Obstet. 2011;33(10):310–314.
   PubMedGoogle Scholar
• Lan YB, Huang YZ, Song Y, et al. Prevalence, severity, and associated factors of menopausal symptoms in middle-aged Chinese women: a community-based cross-sectional study in Southeast China. Menopause. 2017;24(10):1200–1207.
   PubMed Web of Science ®Google Scholar
• Yu CG, Zhao SH, Shi JY, et al. A translational study of low-dose estrogen replacement therapy on Kupperman score and levels of hormones in patients with perimenopausal syndrome. J Int Transl Med. 2016;4:143–146.
   PubMed Web of Science ®Google Scholar
• Polisseni AF, Andrade ATL, Ribeiro LC, et al. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study. Maturitas. 2013;74(2):172–178.
   PubMed Web of Science ®Google Scholar
• Taylor HS, Tal A, Pal L, et al. Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Intern Med. 2017;177(10):1471–1479.
   PubMed Web of Science ®Google Scholar
• Min K. Effect of low-dose estrogen replacement therapy on hormone levels and quality of life of patients with perimenopausal syndrome. China Pharm. 2017;26:41–43.
   Google Scholar
• Huang Y, Chatooah ND, Qi T, et al. Health-related quality of life and its associated factors in Chinese middle-aged women. Climacteric. 2018;21 (5):483–490.
   PubMed Web of Science ®Google Scholar
• Mattsson LA, Ipsen HE, Granqvist CJ, et al. Ultra-low-dose estradiol and norethisterone acetate: bleeding patterns and other outcomes over 52 weeks of therapy. Climacteric. 2015;18(3):419–425.
   PubMed Web of Science ®Google Scholar
• Yim G, Ahn Y, Chang Y, et al. Prevalence and severity of menopause symptoms and associated factors across menopause status in Korean women. Menopause. 2015;22(10):1108–1116.
   PubMed Web of Science ®Google Scholar